Muzaffar H. Qazilbash
- : 713.745.3458
I am a Professor in the department of stem cell transplantation and cellular therapy at UT MD Anderson Cancer Center since October 2002. I completed my hematology-oncology fellowship at the National Institutes of Health (NIH) in Bethesda, Maryland. My clinical and research experience at the NIH was instrumental in defining my career goals. Training in the laboratory provided me with the necessary basic knowledge and skills to perform translational research activities.
I am committed to clinical and translational research. My research interests primarily focus on immune and cellular therapy for cancer. I am the Principal Investigator (PI) for the PR1 vaccine trial (DM97-325). It is an NCI-sponsored study (# T98-0017) that has received national recognition due to its novel approach and encouraging results. I am the PI for two clinical trials that will study the role of PR1 antigen-specific T cell therapy in the treatment of acute (2005-0617) and chronic (2003-0564) myeloid leukemia. Both trials are IRB-approved, and are waiting for patient accrual. These studies have been funded through various institutional and NIH grants. I am the co- principal investigator on a clinical trial using b-interferon secreting mesenchymal stem cells (MSC) in metastatic ovarian cancer. This trial is a part of Ovarian Cancer SPORE grant.
UT-MD Anderson Cancer Center provides an excellent environment and resources to perform high-quality clinical and translational research. I feel that my clinical and research training and my experience as PI on several cell therapy studies have adequately equipped to study the role of MSC in the treatment of metastatic breast cancer in a phase I clinical trial.